| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2010: ¥520,000 (Direct Cost: ¥400,000、Indirect Cost: ¥120,000)
Fiscal Year 2009: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2008: ¥2,860,000 (Direct Cost: ¥2,200,000、Indirect Cost: ¥660,000)
|
|---|
| Research Abstract |
Poorly vascularized solid-tumor cells encounter a range of cytotoxic conditions such as hypoxia and nutrient deprivation, which cause ER stress. These cytotoxic conditions in solid tumors are considered to adapt to ER stress by activating X-box binding protein 1 (XBP1). Therefore, we have been screening for an inhibitor of XBP1 activation, and we succeeded to identify three small molecule inhibitors. As we investigated the molecular mechanism by which these small molecule inhibitors inhibited XBP1, we found that toyocamycin strongly inhibited XBP1 and induced apoptosis in cancer cells only under ER stressed condition. Therefore, toyocamycin would be an inhibitor as a new molecular target therapy of cancer.
|
